Anti-Inflammatory Therapeutics Market

Industry Outlook

The anti-inflammatory therapeutics market is expected to reach US$ 130.6 billion by 2026, growing at an 8.5% CAGR from 2018 to 2026. Biologics and immune-selective anti-inflammatory derivatives (ImSAIDs) are promising drug classes playing a major role in the market. North America clearly holds a major share in the global anti-inflammatory therapeutics market, as the key companies have their headquarters in the region. Non-steroidal anti-inflammatory drugs are used for the treatment of chronic and acute pain. Whether it’s a headache or migraine, a ligament sprain, menstrual pain, or rheumatoid arthritis, anti-inflammatory drugs can treat it faster as compared to other drugs. They are equipped to bring down the level of prostaglandins; the chemicals are responsible for reducing pain, swelling, and inflammation.

The growing prevalence of respiratory and autoimmune diseases increased investment in Asia-Pacific and Europe, and a large number of biologics in the pipeline will drive the growth of the global anti-inflammatory therapeutics market. Factors such as the presence of recognized markets for biologics and corticosteroids and the larger acceptance of OTC NSAIDs, for example, naproxen and ibuprofen, in countries like India and China would additionally enhance the market growth in the Asia Pacific region.

The United States is the leading market in North America at the global level, and Japan is the foremost market for biologic drugs in the Asia Pacific market. While the United Kingdom is projected to lead the market in Europe. Moreover, in Japan, the administration is currently focusing on the establishment of viable generic drugs. Furthermore, China is anticipated to rise as the new market front-runner in the Asia Pacific market by 2026, owing to its rapidly developing economy, developing healthcare facilities, and immense patient base. In India, the introduction of biosimilars and continuously improving healthcare expenses will be the main variables encouraging the development of the anti-inflammatory therapeutics market.

Market Portraiture

“Corticosteroid drugs boost the growth of the anti-inflammatory therapeutics market.”

Currently, corticosteroids are the largest drug type by value and are estimated to retain their prominence, while biologics are expected to record the highest double-digit CAGR throughout the forecast period from 2018–2026. According to the WHO, the prevalence of rheumatoid arthritis contrasts between 0.3% and 1%, which is more typical in women. About 1.5 million people in the United States have rheumatoid arthritis (RA). Corticosteroids are used to treat systemic lupus and severe psoriasis and to suppress the immune system.

“During the forecast period, the IBD segment by indication will have the highest double-digit CAGR.”

According to the CDC (Centers for Disease Control and Prevention), in the US, it is presently projected that around 1 million to 1.3 million people are affected by IBD. Moreover, studies from various nations exhibit that the incidence of IBD is growing, particularly in adolescence. Right now, the highest yearly incidence of IBD (inflammatory bowel disease) in Europe is 12.7 per 100,000 person-years for CD (Crohn’s disease) and 24.3 per 100,000 person-years for UC (ulcerative colitis). In North America, the yearly incidence of IBD was 19.2 per 100,000 men for UC and 20.2 per 100,000 person-years for CD. In Asia and the Middle East, the UC rate was 6.3 for every 100,000 person-years, and the CD rate was 5.0 for every 100,000 person-years. The maximum prevalence for UC was 505 per 100,000 people in Europe and 249 per 100,000 people in North America. The yearly prevalence of CD was 322 per 100,000 people in Europe and 319 per 100,000 people in North America. So, it is expected that these factors will encourage the development of the anti-inflammatory therapeutics market.

Periods of History and Forecast

This detailed study offers an analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each segment is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anti-inflammatory therapeutics market study offers the existing market dynamics along with a quantitative analysis of the global market. The report explains the detailed outline of the global anti-inflammatory therapeutics market by classifying the market in terms of drug type, indication, and geography. The objective of publishing this widespread research report is to support healthcare professionals and market investors in making better conclusions and taking strategic initiatives in the anti-inflammatory therapeutics market.

This detailed study further defines the major qualitative market assessment factors, including the main market driver, market trends, and restraints, to help in a better understanding of the global anti-inflammatory therapeutics market. Each market valuation factor comprising challenges, market drivers, and opportunities is widely elucidated considering the existing market scenario. This report graphically maps the market players based on their market initiatives, product offerings, strategies, and business strengths. Moreover, the report provides an attractive investment proposition based on extensive geographical research. Key players profiled in the report include AbbVie Inc., Amgen Inc., AstraZeneca plc, Eli Lily and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Company, Inc., Novartis International AG, Pfizer Inc., and F. Hoffmann-La Roche AG, among others.

Key questions are answered in this report.

• What are the existing market trends in the anti-inflammatory therapeutics market and the most valuable opportunities for the players?
• How does the regulatory framework affect global as well as regional markets?
• Which is the largest segment by drug type in the anti-inflammatory therapeutics market?
• Which is the fastest-growing segment by drug type in the anti-inflammatory therapeutics market?
• Which is the largest segment by indication in the anti-inflammatory therapeutics market?
• Which is the fastest-growing segment by indication in the anti-inflammatory therapeutics market?
• Which is the fastest-growing regional market?
• How does the FDA’s approval of products affect the global market?
• What are the trends and market size in emerging markets such as Japan, Latin America, and America?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Market Segmentation
1.4. Research Methodology
1.4.1. Phase I-Secondary Research
1.4.2. Phase II-Primary Research
1.4.3. Phase III-Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Anti-inflammatory Therapeutics Market, by Drug Type, 2017 (US$ Bn)
2.2. Global Anti-inflammatory Therapeutics Market, by Indication, 2017 (US$ Bn)
2.3. Global Anti-inflammatory Therapeutics Market, by Geography, 2017 (US$ Bn)

Chapter 3. Global Anti-inflammatory Therapeutics Market Overview, 2016-2026 (US$ Bn)
3.1. Overview
3.2. Market Drivers
3.2.1. Growing Incidence Of Respiratory Diseases And Autoimmune Conditions
3.3. Challenges
3.3.1. Lack of Timely Diagnosis and Access to Care
3.3.2. Challenge 2
3.4. Opportunities
3.4.1. Strong Pipeline Candidates
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Market Competition Assessment, 2017

Chapter 4. Global Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
4.1. Overview
4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
4.3. Corticosteroids
4.4. Biologics
4.5. Immune Selective Anti-inflammatory Derivatives (ImSAIDs)
4.6. Pipeline Analysis (Market estimations Till 2026)
4.6.1. Projected Sale of Phase III Drugs Estimated Till 2026 (US$ Bn)
4.6.1.1. ABT-494
4.6.1.2. ABBV-066
4.6.1.3. Cobitolimod
4.6.2. Qualitative Information on Phase II and I drugs

Chapter 5. Global Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
5.1. Overview
5.2. Rheumatoid Arthritis
5.3. Chronic obstructive pulmonary disease (COPD)
5.4. Multiple Sclerosis
5.5. Inflammatory bowel disease (IBD)
5.6. Psoriatic Arthritis
5.7. Gout
5.8. Others (Osteoarthritis, Systemic lupus, Psoriasis)

Chapter 6. Global Anti-inflammatory Therapeutics Market, by Geography, 2016 – 2026 (US$ Bn)
6.1. Overview
6.2. North America Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
6.2.1. North America Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
6.2.2. North America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
6.2.3. North America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
6.3.1. Europe Anti-inflammatory Therapeutics Market, by Drugs, 2016 – 2026 (US$ Bn)
6.3.2. Europe Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
6.3.3. Europe Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. France
6.3.3.4. Italy
6.3.3.5. Spain
6.3.3.6. Rest of Europe
6.4. Asia Pacific Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
6.4.1. Asia Pacific Anti-inflammatory Therapeutics Market, by Drugs, 2016 – 2026 (US$ Bn)
6.4.2. Asia Pacific Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
6.4.3. Asia Pacific Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
6.5.1. Latin America Anti-inflammatory Therapeutics Market, by Drugs, 2016 – 2026 (US$ Bn)
6.5.2. Latin America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
6.5.3. Latin America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
6.6.1. MEA Anti-inflammatory Therapeutics Market, by Drugs, 2016 – 2026 (US$ Bn)
6.6.2. MEA Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
6.6.3. MEA Anti-inflammatory Therapeutics Market, by Region, 2016 – 2026 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Amgen, Inc.
7.3. AstraZeneca plc
7.4. Eli Lily and Company
7.5. GlaxoSmithKline plc
7.6. Johnson & Johnson
7.7. Merck & Company, Inc.
7.8. Novartis International AG
7.9. AbbVie Inc
7.10. F. Hoffmann-La Roche AG

List of Figures

FIG. 1 Market Segmentation for Anti-inflammatory Therapeutics Market, 2017
FIG. 2 Global Anti-inflammatory Therapeutics Market: Research Methodology
FIG. 3 Global Anti-inflammatory Therapeutics Market, by Drug Type, 2017 (US$ Bn)
FIG. 4 Global Anti-inflammatory Therapeutics Market, by Indication, 2017 (US$ Bn)
FIG. 5 Global Anti-inflammatory Therapeutics Market, by Geography, 2017 (US$ Bn)
FIG. 6 Attractive Investment Proposition: Global Anti-inflammatory Therapeutics Market by Geography, 2017
FIG. 7 Competition Landscape: Anti-inflammatory Therapeutics Market, by Key Players, 2017
FIG. 8 Global Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 9 Global Corticosteroids Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 10 Global Biologics Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 11 Global Immune Selective Anti-inflammatory Derivatives (ImSAIDs) Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 12 Global Rheumatoid Arthritis Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 13 Global COPD (Chronic obstructive pulmonary disease) Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 14 Global Multiple Sclerosis Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 15 Global IBD (Inflammatory bowel disease) Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 16 Global Psoriatic Arthritis Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 17 Global Gout Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 18 Global Others Market for Anti-inflammatory Therapeutics, 2016 – 2026 (US$ Bn)
FIG. 19 U.S. Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 20 Canada Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 21 U.K. Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 22 Germany Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 23 France Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 24 Italy Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 25 Spain Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 26 Rest of Europe Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 27 Japan Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 28 China Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 29 India Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 30 Rest of Asia Pacific Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 31 Brazil Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 32 Mexico Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 33 Rest of Latin America Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 34 GCC Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)
FIG. 35 Rest of Middle East and Africa Anti-inflammatory Therapeutics Market, 2016 – 2026 (US$ Bn)

List of Tables

TABLE 1 Global Anti-inflammatory Therapeutics Market Portraiture
TABLE 2 Global Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 3 Global Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 4 Global Anti-inflammatory Therapeutics Market, by Geography, 2016 – 2026 (US$ Bn)
TABLE 5 North America Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 6 North America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 7 North America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 8 Europe Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 9 Europe Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 10 Europe Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 11 Asia Pacific Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 12 Asia Pacific Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 13 Asia Pacific Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 14 Latin America Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 15 Latin America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 16 Latin America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 17 Middle East and Africa Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 18 Middle East and Africa Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 19 Middle East and Africa Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 20 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Eli Lily and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Merck & Company, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 AbbVie Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)